TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY

被引：0
|
作者：
Bell, J. [1 ]
Galaznik, A. [1 ]
Farrelly, E. [2 ]
Blazer, M. [2 ]
Shih, H-C. [2 ]
Raju, A. [2 ]
Ogbonnaya, A. [2 ]
Eaddy, M. [2 ]
Fram, R. [1 ]
Faller, D. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Xcenda, Palm Harbor, FL USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1196
引用
收藏
页码：491 / 492
页数：2
相关论文
共 50 条
  • [41] Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.
    Hasegawa, Ken
    Wei, Andrew H.
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Rajakumaraswamy, Nishanthan
    Iqbal, Shahed
    Chan, Rebecca J.
    Hu, Hao
    Tse, Preston
    Yan, Jiajun
    Zoratti, Michael J.
    Xie, Feng
    Sallman, David Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] TREATMENT PATTERNS AND TREATMENT RESPONSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN ROUTINE CLINICAL CARE IN THE UNITED STATES - A CLAIMS DATABASE STUDY
    Galaznik, A.
    Bell, J.
    Hamilton, L.
    Ogbonnaya, A.
    Hennenfent, K.
    Eaddy, M.
    Shou, Y.
    HAEMATOLOGICA, 2017, 102 : 688 - 689
  • [43] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [44] Impact of Treatment on Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (MDS): A Report from the Erasme Study
    Arnan, Montserrat
    Coll, Rosa
    Tormo, Mar
    Maria Bastida, Jose
    Calbacho, Maria
    Bernal, Teresa
    Ramos, Fernando
    Somolinos, Nieves
    Pedro, Carmen
    Albors, Manuel
    Marchante, Inmaculada
    Brunet, Salut
    Rafel, Montse
    Valcarcel, David
    BLOOD, 2015, 126 (23)
  • [45] RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)
    Garcia-Manero, G.
    Fenaux, P.
    Al-Kali, A.
    Baer, M. R.
    Sekeres, M.
    Roboz, G.
    Gaidano, G.
    Scott, B.
    Greenberg, P.
    Platzbecker, U.
    Steensma, D. P.
    Kambhampati, S.
    Kreuzer, K. A.
    Godley, L.
    Collins, R.
    Atallah, E.
    Azarnia, N.
    Petrone, M. E.
    Snyder, B. R.
    Maniar, M.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S57 - S58
  • [46] Pevonedistat (P) plus azacitidine (A) vs A alone in higher-risk myelodysplastic syndromes (HR-MDS): efficacy and safety results from study P-2001 (NCT02610777)
    Giagounidis, A.
    Sekeres, M. A.
    Watts, J.
    Radinoff, A.
    Arnan, M.
    Cerrano, M.
    Lopez, Font P.
    Zeidner, J. F.
    Campelo, Diez M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhou, D.
    Friedlander, S.
    Galinsky, K.
    Faller, D., V
    Ades, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 30 - 30
  • [47] Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): US Food and Drug Administration (FDA) Patient-Level Analyses
    Kim, Nina
    Vallejo, Jonathon
    Herz, Jonathan
    Gwise, Thomas
    de Claro, R. Angelo
    Theoret, Marc
    Pazdur, Richard
    Norsworthy, Kelly J.
    BLOOD, 2021, 138
  • [48] PEVONEDISTAT (P) PLUS AZACITIDINE (A) VS A ALONE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS): EFFICACY AND SAFETY RESULTS FROM STUDY P-2001 (NCT02610777)
    Santini, V.
    Sekeres, M. A.
    Watts, J.
    Radinoff, A.
    Arnan, M.
    Cerrano, M.
    Font Lopez, P.
    Zeidner, J. F.
    Diez Campelo, M.
    Graux, C.
    Liesveld, J.
    Selleslag, D.
    Tzvetkov, N.
    Fram, R. J.
    Zhao, D.
    Friedlander, S.
    Galinsky, K.
    Faller, D. V.
    Ades, L.
    HAEMATOLOGICA, 2021, 106 (10) : 2 - 3
  • [49] INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs) Study design informed by subgroup analyses of ONTIME.
    Garcia-Manero, Guillermo
    Al-Kali, Aref
    Baer, Maria R.
    Robor, Gail J.
    Platzbecker, Uwe
    Kambhampati, Suman
    Godley, Lucy A.
    Collins, Robert
    Shammo, Jamile M.
    Santini, Valeria
    Raza, Azra
    Silverman, Lewis R.
    Azarnia, Nozar
    Fruchtman, Steven M.
    Snyder, Barbara R.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Clinical Outcome of 40 Patients with Higher-Risk Myelodysplastic Syndromes (MDS) after Treatment with Hypomethylating Agents: a Matched-Pairs Analysis.
    Nachtkamp, Kathrin
    Strupp, Corinna
    Kuendgen, Andrea
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    BLOOD, 2008, 112 (11) : 929 - 929
12345